VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of medicines for the treatment of cancer, and respiratory and autoimmune diseases. The company focuses on the development of small molecule product candidates targeting toll-like receptor 8 (TLR8) agonists and antagonists. Its product pipeline comprises VTX-2337, a small molecule TLR8 agonist that stimulates myeloid dendritic cells and monocytes, and enhances natural killer cell responses for the treatment of solid tumors, ovarian and breast cancers, and NHL and SCHN; VTX-1463, a stand alone agent for the treatment of seasonal and perennial allergies; TLR8 antagonists for the treatment of autoimmune diseases; and multiple compounds that are treated as vaccine adjuvants. The company has a strategic agreement/collaboration with Celgene Corporation. VentiRx Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Seattle, Washington with operations in San Diego.
Current Team (10)Update
Director, Product Development
VP, Regulatory Affairs
VP, Business Development & Alliance Management
Co - Founder
Chief Medical Officer
CEO & Board Member
Senior Director, Clinical Affairs
Funding Rounds (2) - $86.6MUpdate
Board Members and Advisors (6)Update
Celgene discovers, develops and commercializes innovative therapies to treat cancer and...
Founded in 1991, Frazier Healthcare Ventures is one of the leading providers of venture and...
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on...
ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs,...
1191 Second Avenue
Seattle, WA 98101